Markets

News Details

( 05/01/2018 15:06)
Lupin unveils generic Ancobon capsules in US

Leading pharma major Lupin has said that it has launched Flucytosine capsules, used to treat serious infections, in the American market.

“The company has launched its generic product in the strengths of 250 mg and 500 mg after having received approval from the US Food and Drug Administration (USFDA),” Lupin said in a filing to the Bombay Stock Exchange.

The Mumbai-based company's product is the generic version of Valeant Pharmaceuticals International Inc's Ancobon tablets. The drug is indicated for the treatment of serious infections.

As per the latest IMS sales data, Flucytosine capsules have annual sales of around USD 48 million in the US.

Meanwhile, shares of the company were trading at Rs 899.80 apiece, up 2.54 per cent from the previous close at 15:12 hrs on BSE.

ATTENTION INVESTORS "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION